Cabaletta Bio, Inc. (CABA)
CABA Stock Price Chart
Explore Cabaletta Bio, Inc. interactive price chart. Choose custom timeframes to analyze CABA price movements and trends.
CABA Company Profile
Discover essential business fundamentals and corporate details for Cabaletta Bio, Inc. (CABA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Oct 2019
Employees
161.00
Website
https://www.cabalettabio.comCEO
Steven A. Nichtberger
Description
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
CABA Financial Timeline
Browse a chronological timeline of Cabaletta Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.37, while revenue estimate is $1.67m.
Earnings released on 14 May 2026
EPS came in at -$0.39 surpassing the estimated -$0.41 by +4.88%.
Earnings released on 23 Mar 2026
EPS came in at -$0.40 surpassing the estimated -$0.45 by +11.11%.
Earnings released on 10 Nov 2025
EPS came in at -$0.44 surpassing the estimated -$0.49 by +10.20%.
Earnings released on 7 Aug 2025
EPS came in at -$0.73 falling short of the estimated -$0.71 by -2.82%.
Earnings released on 15 May 2025
EPS came in at -$0.71 falling short of the estimated -$0.67 by -5.97%.
Earnings released on 31 Mar 2025
EPS came in at -$0.65 matching the estimated -$0.65, while revenue for the quarter reached $1.64m .
Earnings released on 14 Nov 2024
EPS came in at -$0.62 falling short of the estimated -$0.59 by -5.08%.
Earnings released on 8 Aug 2024
EPS came in at -$0.56 falling short of the estimated -$0.55 by -1.82%.
Earnings released on 15 May 2024
EPS came in at -$0.51 falling short of the estimated -$0.48 by -6.25%.
Earnings released on 21 Mar 2024
EPS came in at -$0.46 falling short of the estimated -$0.39 by -17.95%, while revenue for the quarter reached $4.01m .
Earnings released on 9 Nov 2023
EPS came in at -$0.37 surpassing the estimated -$0.39 by +5.13%.
Earnings released on 10 Aug 2023
EPS came in at -$0.37 surpassing the estimated -$0.47 by +21.28%.
Earnings released on 11 May 2023
EPS came in at -$0.45 surpassing the estimated -$0.48 by +6.25%.
Earnings released on 16 Mar 2023
EPS came in at -$0.52 falling short of the estimated -$0.47 by -10.64%.
Earnings released on 10 Nov 2022
EPS came in at -$0.39 surpassing the estimated -$0.49 by +20.41%.
Earnings released on 11 Aug 2022
EPS came in at -$0.45 surpassing the estimated -$0.52 by +13.46%.
Earnings released on 12 May 2022
EPS came in at -$0.45 surpassing the estimated -$0.64 by +29.69%.
Earnings released on 17 Mar 2022
EPS came in at -$0.49 surpassing the estimated -$0.68 by +27.94%.
Earnings released on 1 Nov 2021
EPS came in at -$0.45 surpassing the estimated -$0.52 by +13.46%.
Earnings released on 5 Aug 2021
EPS came in at -$0.45 surpassing the estimated -$0.51 by +11.76%.
CABA Stock Performance
Access detailed CABA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
